
A study has found that liquid biopsy is an effective method for detecting EGFR mutations in advanced non-small cell lung cancer (NSCLC). The study analyzed data from 100 patients with advanced NSCLC. The researchers found that liquid biopsy concords with tissue testing in 90% of cases. The median time to results for liquid biopsy was also shorter than for tissue testing (9 days vs. 26 days). These findings suggest that liquid biopsy is a valuable tool for diagnosing and monitoring EGFR-mutated NSCLC.
Like
Save
Share